NCT04218435 - Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

October 25, 2020

Study Completion Date

December 30, 2020

Conditions

Heart Failure NYHA Class IVHeart Failure NYHA Class II

Interventions

DRUG

Sacubitril / Valsartan Oral Tablet

"Sacubitril/Valsartan is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.~Sacubitril/Valsartan is usually administered in conjunction with another heart failure therapies, in place of an ACE inhibitor or other ARB."

Trial Locations (1)

54590

Doctors hospital and medical center, Lahore